Nanoparticle-based non-viral CRISPR delivery for enhanced immunotherapy

Area of Science:

• Biotechnology
• Molecular Biology
• Immunotherapy

Background:

• CRISPR-Cas9 is a powerful gene editing tool with significant therapeutic potential.
• Its application in immunotherapy is a key area of research.
• Current delivery methods face challenges like low efficiency and immune responses.

Purpose of the Study:

• To review recent advancements in CRISPR-Cas9 delivery using non-viral carriers for immunotherapy.
• To explore nanoparticle-based strategies for overcoming delivery limitations.
• To discuss future research directions in this field.

Main Methods:

• Review of current literature on CRISPR-Cas9 delivery systems.
• Focus on non-viral carriers, particularly nanoparticles.
• Analysis of applications based on targeted cell types in immunotherapy.

Main Results:

• Nanoparticles offer a viable alternative to physical and viral delivery methods.
• Non-viral carriers can improve cell viability, reduce immune response, and enhance targeting.
• Diverse nanoparticle types are being developed for CRISPR delivery.

Conclusions:

• Non-viral carriers, especially nanoparticles, are crucial for advancing CRISPR-based immunotherapy.
• Further research is needed to optimize these delivery systems for clinical applications.
• CRISPR-mediated non-viral delivery holds significant promise for future immunotherapies.